GNPX – Genprobe Incorporated
GNPX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
10.71
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
Price
0.83
Target Price
375
Analyst Recom
1
Performance Q
-63.83
Upside
-24,292.7%
Beta
-0.95
Ticker: GNPX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-23 | GNPX | 1.02 | N/A | N/A | 0 |
| 2026-04-24 | GNPX | 1.02 | N/A | N/A | 0 |
| 2026-04-27 | GNPX | 0.9378 | N/A | N/A | 0 |
| 2026-04-28 | GNPX | 0.9277 | N/A | N/A | 0 |
| 2026-04-29 | GNPX | 0.863 | N/A | N/A | 0 |
| 2026-04-30 | GNPX | 0.9723 | N/A | N/A | 0 |
| 2026-05-01 | GNPX | 0.9194 | N/A | N/A | 0 |
| 2026-05-04 | GNPX | 0.93 | N/A | N/A | 0 |
| 2026-05-05 | GNPX | 0.8852 | N/A | N/A | 0 |
| 2026-05-06 | GNPX | 0.9002 | N/A | N/A | 0 |
| 2026-05-07 | GNPX | 0.8709 | N/A | N/A | 0 |
| 2026-05-08 | GNPX | 0.8649 | N/A | N/A | 0 |
| 2026-05-11 | GNPX | 0.8507 | N/A | N/A | 0 |
| 2026-05-12 | GNPX | 0.8301 | N/A | N/A | 0 |
| 2026-05-13 | GNPX | 0.8492 | N/A | N/A | 0 |
| 2026-05-14 | GNPX | 0.87 | N/A | N/A | 0 |
| 2026-05-15 | GNPX | 0.8336 | N/A | N/A | 0 |
| 2026-05-18 | GNPX | 0.8161 | N/A | N/A | 0 |
| 2026-05-19 | GNPX | 0.778 | N/A | N/A | 0 |
| 2026-05-20 | GNPX | 0.78 | N/A | N/A | 0 |
| 2026-05-21 | GNPX | 0.8124 | N/A | N/A | 0 |
| 2026-05-22 | GNPX | 0.8291 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-23 | GNPX | 1.03 | - | - | - |
| 2026-04-24 | GNPX | 1.01 | - | - | - |
| 2026-04-27 | GNPX | 0.94 | - | - | - |
| 2026-04-28 | GNPX | 0.92 | - | - | - |
| 2026-04-29 | GNPX | 0.86 | - | - | - |
| 2026-04-30 | GNPX | 0.97 | - | - | - |
| 2026-05-01 | GNPX | 0.92 | - | - | - |
| 2026-05-04 | GNPX | 0.93 | - | - | - |
| 2026-05-05 | GNPX | 0.89 | - | - | - |
| 2026-05-06 | GNPX | 0.89 | - | - | - |
| 2026-05-07 | GNPX | 0.87 | - | - | - |
| 2026-05-08 | GNPX | 0.87 | - | - | - |
| 2026-05-11 | GNPX | 0.85 | - | - | - |
| 2026-05-12 | GNPX | 0.84 | - | - | - |
| 2026-05-13 | GNPX | 0.85 | - | - | - |
| 2026-05-14 | GNPX | 0.87 | - | - | - |
| 2026-05-15 | GNPX | 0.84 | - | - | - |
| 2026-05-18 | GNPX | 0.81 | - | - | - |
| 2026-05-19 | GNPX | 0.78 | - | - | - |
| 2026-05-20 | GNPX | 0.79 | - | - | - |
| 2026-05-21 | GNPX | 0.81 | - | - | - |
| 2026-05-22 | GNPX | 0.83 | - | - | - |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-23 | GNPX | -0.00 | 0.12 | 4.47 |
| 2026-04-24 | GNPX | -0.00 | 0.12 | 4.47 |
| 2026-04-27 | GNPX | -0.00 | 0.19 | 5.75 |
| 2026-04-28 | GNPX | -0.00 | 0.19 | 5.75 |
| 2026-04-29 | GNPX | -0.00 | 0.19 | 5.75 |
| 2026-04-30 | GNPX | -0.00 | 0.19 | 5.75 |
| 2026-05-01 | GNPX | -0.00 | 0.19 | 5.75 |
| 2026-05-04 | GNPX | -0.00 | 0.63 | 5.75 |
| 2026-05-05 | GNPX | -0.00 | 0.63 | 5.75 |
| 2026-05-06 | GNPX | -0.00 | 0.63 | 5.75 |
| 2026-05-07 | GNPX | -0.00 | 0.63 | 5.75 |
| 2026-05-08 | GNPX | -0.00 | 0.63 | 5.75 |
| 2026-05-11 | GNPX | -0.00 | 0.60 | 5.74 |
| 2026-05-12 | GNPX | -0.00 | 0.60 | 12.75 |
| 2026-05-13 | GNPX | -0.00 | 0.60 | 12.75 |
| 2026-05-14 | GNPX | -0.00 | 0.60 | 12.33 |
| 2026-05-15 | GNPX | -0.02 | 0.60 | 12.33 |
| 2026-05-18 | GNPX | -0.02 | 0.60 | 0 |
| 2026-05-19 | GNPX | -0.02 | 0.60 | 10.71 |
| 2026-05-20 | GNPX | -0.02 | 0.60 | 10.71 |
| 2026-05-21 | GNPX | -0.02 | 0.60 | 10.71 |
| 2026-05-22 | GNPX | -0.02 | 0.60 | 10.71 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.42
Avg. EPS Est. Next Quarter
Insider Transactions
-0.02
Institutional Transactions
0.6
Beta
-0.95
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
15
Growth Score
Sentiment Score
13
Actual DrawDown %
100
Max Drawdown 5-Year %
-100
Target Price
375
P/E
Forward P/E
PEG
P/S
P/B
0.44
P/Free Cash Flow
EPS
-15.26
Average EPS Est. Cur. Y
EPS Next Y. (Est.)
-1.15
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.26
Return on Equity vs Sector %
-125.9
Return on Equity vs Industry %
-110.2
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
GNPX
Healthcare
$0.82
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
31
Range 1M
25.8%
Sup Dist
3.6%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
0%
EPS NY
0%
52W%
0.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+45631.7% upside
Upside
+45631.7%
Quality
15
Genprex, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 13
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. It also develops REQORSA Gene Therapy in Mesothelioma, Ras Inhibitor Resistant NSCLC, other tumor suppressor genes, and Glioblastoma, which is in preclinical studies. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive; New York University; UTHealth Houston; and University of Pittsburgh. The company also has a sponsored research agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that for the prediction of patient response to Reqorsa Gene Therapy. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.
GNPX
Latest News
—
Caricamento notizie per GNPX…
stock quote shares GNPX – Genprobe Incorporated Stock Price stock today
news today GNPX – Genprobe Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch GNPX – Genprobe Incorporated yahoo finance google finance
stock history GNPX – Genprobe Incorporated invest stock market
stock prices GNPX premarket after hours
ticker GNPX fair value insiders trading